JP7656608B2 - トラピジルを使用した認知障害の治療 - Google Patents

トラピジルを使用した認知障害の治療 Download PDF

Info

Publication number
JP7656608B2
JP7656608B2 JP2022530822A JP2022530822A JP7656608B2 JP 7656608 B2 JP7656608 B2 JP 7656608B2 JP 2022530822 A JP2022530822 A JP 2022530822A JP 2022530822 A JP2022530822 A JP 2022530822A JP 7656608 B2 JP7656608 B2 JP 7656608B2
Authority
JP
Japan
Prior art keywords
per day
trapidil
pharma
acid
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504004A5 (https=
JP2023504004A (ja
Inventor
ボードバー，アーラッシュ
Original Assignee
シノピア バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シノピア バイオサイエンシーズ，インク． filed Critical シノピア バイオサイエンシーズ，インク．
Publication of JP2023504004A publication Critical patent/JP2023504004A/ja
Publication of JP2023504004A5 publication Critical patent/JP2023504004A5/ja
Priority to JP2025047264A priority Critical patent/JP2025111439A/ja
Application granted granted Critical
Publication of JP7656608B2 publication Critical patent/JP7656608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022530822A 2019-12-02 2020-12-01 トラピジルを使用した認知障害の治療 Active JP7656608B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025047264A JP2025111439A (ja) 2019-12-02 2025-03-21 トラピジルを使用した認知障害の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942645P 2019-12-02 2019-12-02
US62/942,645 2019-12-02
PCT/US2020/062751 WO2021113266A1 (en) 2019-12-02 2020-12-01 Treating cognitive disorders using trapidil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025047264A Division JP2025111439A (ja) 2019-12-02 2025-03-21 トラピジルを使用した認知障害の治療

Publications (3)

Publication Number Publication Date
JP2023504004A JP2023504004A (ja) 2023-02-01
JP2023504004A5 JP2023504004A5 (https=) 2023-12-04
JP7656608B2 true JP7656608B2 (ja) 2025-04-03

Family

ID=76221925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530822A Active JP7656608B2 (ja) 2019-12-02 2020-12-01 トラピジルを使用した認知障害の治療
JP2025047264A Pending JP2025111439A (ja) 2019-12-02 2025-03-21 トラピジルを使用した認知障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025047264A Pending JP2025111439A (ja) 2019-12-02 2025-03-21 トラピジルを使用した認知障害の治療

Country Status (7)

Country Link
US (1) US20220378794A1 (https=)
EP (1) EP4069239A4 (https=)
JP (2) JP7656608B2 (https=)
CN (1) CN115397425A (https=)
AU (1) AU2020398858B2 (https=)
CA (1) CA3163242A1 (https=)
WO (1) WO2021113266A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695338B2 (en) * 2015-05-07 2020-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
MX2022011879A (es) 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026126A1 (ja) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Ｃｒｆ拮抗剤および二環式複素環化合物
JP2019510826A (ja) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02212488A (ja) * 1989-02-13 1990-08-23 Shinichiro Shimizu トリアゾールピリミジン誘導体
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
JP2021524837A (ja) * 2018-04-13 2021-09-16 ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ 脆弱ｘ症候群のためのキット、組成物および併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026126A1 (ja) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Ｃｒｆ拮抗剤および二環式複素環化合物
JP2019510826A (ja) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
医学と薬学，1986年，第16巻，第2号，p.609-616
基礎と臨床，1985年，Vol.19，No.7 ，p.3393-3400 (p.345-352)
基礎と臨床，1987年，Vo1.21，No.12，p.5025-5030 (p.189-194)

Also Published As

Publication number Publication date
CA3163242A1 (en) 2021-06-10
EP4069239A4 (en) 2023-11-29
AU2020398858B2 (en) 2026-02-19
AU2020398858A1 (en) 2022-06-30
CN115397425A (zh) 2022-11-25
WO2021113266A1 (en) 2021-06-10
JP2025111439A (ja) 2025-07-30
EP4069239A1 (en) 2022-10-12
JP2023504004A (ja) 2023-02-01
US20220378794A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US20250025448A1 (en) Methods of increasing tonic inhibition and treating secondary insomnia
US12268691B2 (en) Treating extrapyramidal syndrome using trapidil
JP2025111439A (ja) トラピジルを使用した認知障害の治療
US20100298394A1 (en) Antifungal agents as neuroprotectants
JP2018518499A (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
US20190111059A1 (en) Compositions and methods for treating autism spectrum disorder
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
US20150313903A1 (en) Methods of treating cognitive impairment associated with neurodegenerative disorders
BR112021010720A2 (pt) Métodos para tratar ou prevenir gota ou hiperuricemia
US10844071B2 (en) Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
WO2017218815A1 (en) Motor-associated neurodegenerative disease and methods of treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250324

R150 Certificate of patent or registration of utility model

Ref document number: 7656608

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150